Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 34 systematic review(s)/meta-analysis(es). ^[1-34]
• Psoriasis: Risankizumab (Skyrizi) demonstrates high effectiveness with superior outcomes in achieving Psoriasis Area and Severity Index (PASI) 75, PASI 90, and PASI 100 compared to placebo and other biologics, particularly in biologic-naive patients, with drug survival rates reported to be higher than those for secukinumab, ixekizumab, and brodalumab.
• Psoriatic Arthritis (PsA): Risankizumab showed significantly higher ACR20 and minimal disease activity (MDA) response rates compared to placebo, with comparable efficacy observed in both biologic-naive and experienced patients, along with notable improvements in work productivity after 24 weeks of treatment.
• Crohn’s Disease (CD): Statistically significant efficacy of risankizumab was noted across various clinical and endoscopic parameters, showing greater effectiveness in biologic-naive patients compared to biologic-experienced ones, and superior to vedolizumab in inducing remission.
• Psoriasis: Risankizumab (Skyrizi) has a safety profile comparable to other biologics, showing no significant increase in serious adverse events compared to placebo. Common adverse events include nasopharyngitis, headache, upper respiratory tract infection, and back pain.
• PsA: Similar to psoriasis, risankizumab demonstrated no significant differences in serious adverse events compared to placebo, with overall adverse event incidence not significantly different. The safety profile aligns closely with other IL-23 inhibitors and tumor necrosis factor (TNF) inhibitors.
• CD: Risankizumab is well-tolerated, with most adverse events classified as mild. The incidence and severity of adverse effects were comparable to those observed with other biologics, such as guselkumab and ustekinumab.
• Risankizumab (Skyrizi) demonstrates higher drug survival rates in biologic-naive patients with psoriasis compared to experienced patients, indicating a potential advantage in this subgroup. The studies included adults over 18 years, with no specific age or gender differences noted in effectiveness.
• In PsA, risankizumab showed comparable efficacy in both biologic-naive and experienced patients, along with significant improvements in work productivity and activity impairment after 24 weeks of treatment. Additionally, higher efficacy was noted in biologic-naive patients with CD compared to those who were biologic-experienced.